Global Menopausal Hot Flashes Market - 2023-2030
Global Menopausal Hot Flashes Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Menopausal hot flashes are the most common symptoms observed in 50-55 years women during menopause. It is caused by hormone fluctuation, especially estrogen; heart palpitations and dizziness can accompany this symptom. Hormone-infused drugs are used to treat hot flashes, which is preferred mostly.
According to John Hopkin's Medicine, 2023, About 75% of all women have these sudden, brief, periodic increases in their body temperature. Usually, hot flashes start before a woman's last period. For 80% of women, hot flashes occur for two years or less. The treatment includes hormonal therapy, antidepressants, etc. However, estrogen therapy is the most effective treatment for relieving menopausal hot flashes.
Market Dynamics: Drivers & Restraints
Increasing menopausal women
Menopause is one of the most common conditions every woman has to go through once in life. The symptoms vary in individuals, such as hot flashes, night sweats, pain during sexual intercourse, mood swings, etc. It occurs at 50-55 in most women: the U.S. census data more than 15 million women ages 45 to 60 in the workplace. An increase in number of menopausal women worldwide is observed according to the data provided.
Menopause occurs at a median age of 51.3 years in the United States. National Institute of Health, in 2023, stated that nearly 80% of women worldwide suffer from vasomotor symptoms (VMS) that can range in severity and affect quality of life and overall health.
According to Mayo Clinic, 2022, By 2030, the world population of menopausal and postmenopausal women is projected to increase to 1.2 billion, with 47 million new entrants each year.
Furthermore, increase in expenditure of women in menopause care, increase in awareness among women, rising advancements in drug discoveries are few factors that are expected to drive the market in the forthcoming period.
Side effects of Hormonal drugs
Side effects of hormone therapy include an increased risk of endometrial cancer with long-term use. Increased risk of blood clots and stroke are observed. If the hormone therapy was started at early stages due to early menopause, there is an increased chance of dementia in women. Gallstones and gallstone problems are also common if the medication is continued for a long time.
Segment Analysis
The global menopausal hot flashes are segmented based on treatment, route of administration, distribution channel and region.
The Hormone therapy segment accounted for approximately 43.1% of the market share
Hormone therapy is expected to hold the largest share of the market. For instance, the imbalance of hormones like estrogen is the main reason for menopausal symptoms. A decrease in the level of hormones shows extreme symptoms (hot flashes, night sweats). A few healthcare startups launched hormonal supplements to combat the hot flashes in most women.
For instance, in August 2023, Rebalance Health, a startup, launched lozenges to help rebalance hormones in menopausal women who experience symptoms like hot flashes, night sweats, etc.
Furthermore, in May 2022, Hologram Sciences launched Phenology, a beauty and wellness brand with curated nutritional supplements to lower the symptoms of menopause, such as hot flashes, night sweats, mood swings, etc.
In April 2023, pH-D Feminine Health launched a new line of oral supplements to support women's menopausal health.
Geographical Analysis
North America accounted for approximately 40.2% of the market share in 2022
North America is expected to hold the largest market share due to the presence of women who experience menopausal symptoms increasing actively in the US. For instance, according to Cuyuna Regional Medical Organisation, in 2022, sixty-four million US women are 50 and older who are at menopausal age.
The cost of menopausal care is also increasing in the US because more working women are present in the US who are older than 45. For instance, according to The New York Times, 2023, Menopause costs American women an estimated $1.8 billion in lost working time per year.
According to the North American Menopause Society, 2023 By 2025, the number of postmenopausal women is expected to rise to 1.1 billion worldwide.
COVID-19 Impact Analysis
COVID-19 impact is moderate or less on the menopausal hot flashes market. Due to the rise in COVID-19 cases, there was a shift in the focus on developing drugs and vaccines to treat covid 19. The supply chain has been disrupted due to the implementation of lockdowns; this has the most impact on this market. As it is only managed and cannot be treated, home remedies were also considered as people feared visiting hospitals because of the infection spread.
Competitive Landscape
The major global players in the menopausal hot flashes market include Pfizer Inc., AbbVie Inc., Bayer, Amneal Pharmaceuticals LLC, Serum Institute of India Pvt. Ltd., Cipla Limited, Camber Pharmaceuticals, Inc., Merck KGaA, Algen Healthcare Ltd, Biosynth among others.
Key Developments
• In May 2023, Veozah (fezolinetant) developed by Astellas Pharma US, Inc. received US Food and Drug Administration approval for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause.
• In October 2023, Elda Health launched a curated product portfolio to expand its horizons. It is based in India and hence aims to empower Indian women who are suffering from menopause.
Why Purchase the Report?
• To visualize the global menopausal hot flashes market segmentation based on treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of menopausal hot flashes market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global menopausal hot flashes market report would provide approximately 61 tables, 57 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Treatment
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Driver
- 4.1.1.1. Increasing menopausal women
- 4.1.1.2. YY
- 4.1.2. Restraints
- 4.1.2.1. Side effects of hormonal drugs
- 4.1.2.2. YY
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Menopausal women stats
- 5.5. Regional Analysis
- 5.6. Regulatory Analysis
- 5.7. DMI Opinion
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Treatment
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 7.1.2. Market Attractiveness Index, By Treatment
- 7.2. Hormone Therapy*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.2.1. Estrogen
- 7.2.2.1.1. Premarin
- 7.2.2.1.2. Vivelle-Dot
- 7.2.2.1.3. Others
- 7.2.2.2. Progesterone
- 7.2.2.2.1. Prometrium
- 7.2.2.2.2. Others
- 7.2.2.3. Combination
- 7.2.2.3.1. Prempro
- 7.2.2.3.2. Duavee
- 7.3. Antidepressants
- 7.3.1. Paroxetine
- 7.3.2. Venlafaxine
- 7.4. Others
- 8. By Route of Administration
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Oral*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Injectables
- 8.4. Others
- 9. By Distribution Channel
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacies
- 9.4. Online Pharmacies
- 10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. UK
- 10.3.6.3. France
- 10.3.6.4. Italy
- 10.3.6.5. Spain
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. Australia
- 10.5.6.5. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 12. Company Profiles
- 12.1. Pfizer Inc.
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. AbbVie Inc.
- 12.3. Bayer
- 12.4. Amneal Pharmaceuticals LLC
- 12.5. Serum Institute of India Pvt. Ltd.
- 12.6. Cipla Limited
- 12.7. Camber Pharmaceuticals, Inc.
- 12.8. Merck KGaA
- 12.9. Algen Healthcare Ltd
- 12.10. Biosynth
- LIST NOT EXHAUSTIVE
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook